-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 5th, Janssen China signed a memorandum of strategic cooperation with Aide Biotech
.
It is understood that in this cooperation, Janssen China will work with local diagnostic companies to drive the innovative pharmaceutical ecosystem, aiming to continuously optimize the full life cycle of drugs, empower patients throughout the course of disease management, improve patient benefits, and help "Healthy China 2030"
.
According to the strategic cooperation memorandum, the two companies will jointly create an end-to-end collaborative innovation service model, covering market access, doctor-patient education, research and development of new biomarkers, and the establishment of a big data platform
.
In addition, the two parties will also cooperate to achieve resource interaction and interconnection, carry out high-quality doctor-patient education on diseases, treatment and diagnosis, and collaborate to promote the integration of precision medicine and diagnosis and treatment to improve patient benefits
.
It is worth mentioning that, in fact, on December 3rd not long before, Aide Biotech just announced the signing of a strategic cooperation agreement with Bohao Biotech to reach a corporate strategic cooperation on genomics research related to tumor precision medicine
.
It is understood that Aide Bio has been focusing on the field of molecular diagnosis of tumor precision medicine.
Through this cooperation, Bohao Biosciences can integrate the cutting-edge expertise and service advantages in the field of genomics and Aide Bio’s expertise in the field of molecular detection of tumor precision medicine.
The advantages of technological advantages and transformational capabilities accelerate the research and exploration of oncology precision medicine, empower clinical translational medicine research and achievement transformation, and realize the seamless integration of clinical experts, innovative pharmaceutical companies, cutting-edge technology and product transformation
.
The industry believes that the above is actually a manifestation of the new trend of the industry in cooperation between pharmaceutical companies and precision diagnosis companies
.
It is reported that in recent days, apart from Yangsen China and Aide Biotech, there have been many cooperations between pharmaceutical companies on diagnosis
.
For example, on November 30, AstraZeneca's Global R&D China Center announced a cooperation with Genetron Health Technology
.
According to the agreement, the two parties will jointly invest and cooperate in solid tumor MRD research and development.
Based on the gene mutation profile of each patient's primary tumor, they will jointly develop and verify personalized customized MRD detection products for efficacy evaluation and tumor recurrence monitoring
.
At the same time, the two parties will establish a joint committee to oversee product development
.
In addition, AstraZeneca also plans to apply the above-mentioned products developed in cooperation with Genetron Health to clinical trials involving customized solid tumor MRD detection in China
.
On November 23, Jiuqiang Biotech and Zhongkonate also held a cooperation signing ceremony
.
This in-depth cooperation between the two parties includes two levels: one is the equity investment of Nine Biotech Co.
, Ltd.
; the other is the signing of a sales cooperation agreement between Nine Biotech and China Conatech, becoming the head of the domestic medical institution for the entire line of CTC products of China Conatech.
Dealer
.
It is expected that through this cooperation, the technical advantages of Zhongkenathai in the field of CTC liquid biopsy will be organically combined with the powerful channel capabilities of the nine-strong biological in the field of inspection, and jointly create a professional enterprise for multi-faceted accurate tumor diagnosis
.
On the whole, analysts believe that a large number of companies are vying to deploy in the field of accurate tumor diagnosis, mainly because they are optimistic about the development prospects of this field
.
It is understood that in recent years, the financing environment of China's diagnostic and genetic testing industry has begun to tighten further, with significant head effects in the field of private equity financing, and genetic testing companies have been at the forefront in terms of the number of transactions and the amount of financing
.
In the future, as the clinical promotion of tumor-targeted drugs continues to accelerate, molecular diagnostic reagents for tumor precision medicine, as the necessary diagnostic procedures for their clinical drugs, will have an increasingly broad market prospect
.
Affected by this, the cooperation between domestic and foreign pharmaceutical companies and local related companies and platforms will also become more frequent
.
.
It is understood that in this cooperation, Janssen China will work with local diagnostic companies to drive the innovative pharmaceutical ecosystem, aiming to continuously optimize the full life cycle of drugs, empower patients throughout the course of disease management, improve patient benefits, and help "Healthy China 2030"
.
According to the strategic cooperation memorandum, the two companies will jointly create an end-to-end collaborative innovation service model, covering market access, doctor-patient education, research and development of new biomarkers, and the establishment of a big data platform
.
In addition, the two parties will also cooperate to achieve resource interaction and interconnection, carry out high-quality doctor-patient education on diseases, treatment and diagnosis, and collaborate to promote the integration of precision medicine and diagnosis and treatment to improve patient benefits
.
It is worth mentioning that, in fact, on December 3rd not long before, Aide Biotech just announced the signing of a strategic cooperation agreement with Bohao Biotech to reach a corporate strategic cooperation on genomics research related to tumor precision medicine
.
It is understood that Aide Bio has been focusing on the field of molecular diagnosis of tumor precision medicine.
Through this cooperation, Bohao Biosciences can integrate the cutting-edge expertise and service advantages in the field of genomics and Aide Bio’s expertise in the field of molecular detection of tumor precision medicine.
The advantages of technological advantages and transformational capabilities accelerate the research and exploration of oncology precision medicine, empower clinical translational medicine research and achievement transformation, and realize the seamless integration of clinical experts, innovative pharmaceutical companies, cutting-edge technology and product transformation
.
The industry believes that the above is actually a manifestation of the new trend of the industry in cooperation between pharmaceutical companies and precision diagnosis companies
.
It is reported that in recent days, apart from Yangsen China and Aide Biotech, there have been many cooperations between pharmaceutical companies on diagnosis
.
For example, on November 30, AstraZeneca's Global R&D China Center announced a cooperation with Genetron Health Technology
.
According to the agreement, the two parties will jointly invest and cooperate in solid tumor MRD research and development.
Based on the gene mutation profile of each patient's primary tumor, they will jointly develop and verify personalized customized MRD detection products for efficacy evaluation and tumor recurrence monitoring
.
At the same time, the two parties will establish a joint committee to oversee product development
.
In addition, AstraZeneca also plans to apply the above-mentioned products developed in cooperation with Genetron Health to clinical trials involving customized solid tumor MRD detection in China
.
On November 23, Jiuqiang Biotech and Zhongkonate also held a cooperation signing ceremony
.
This in-depth cooperation between the two parties includes two levels: one is the equity investment of Nine Biotech Co.
, Ltd.
; the other is the signing of a sales cooperation agreement between Nine Biotech and China Conatech, becoming the head of the domestic medical institution for the entire line of CTC products of China Conatech.
Dealer
.
It is expected that through this cooperation, the technical advantages of Zhongkenathai in the field of CTC liquid biopsy will be organically combined with the powerful channel capabilities of the nine-strong biological in the field of inspection, and jointly create a professional enterprise for multi-faceted accurate tumor diagnosis
.
On the whole, analysts believe that a large number of companies are vying to deploy in the field of accurate tumor diagnosis, mainly because they are optimistic about the development prospects of this field
.
It is understood that in recent years, the financing environment of China's diagnostic and genetic testing industry has begun to tighten further, with significant head effects in the field of private equity financing, and genetic testing companies have been at the forefront in terms of the number of transactions and the amount of financing
.
In the future, as the clinical promotion of tumor-targeted drugs continues to accelerate, molecular diagnostic reagents for tumor precision medicine, as the necessary diagnostic procedures for their clinical drugs, will have an increasingly broad market prospect
.
Affected by this, the cooperation between domestic and foreign pharmaceutical companies and local related companies and platforms will also become more frequent
.
